Journavx (suzetrigine) Letter of Medical Necessity
Journavx (suzetrigine) is the first FDA-approved selective NaV1.8 inhibitor and the first new class of acute pain medication in decades. Many plans still treat it as non-formulary or require generic analgesic step therapy. Prescribers can win coverage by documenting opioid risk factors, NSAID contraindications, and the clinical need for a non-opioid option.
FDA-Approved Indications
- ● moderate-to-severe acute pain in adults
Why Journavx Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy: generic NSAIDs, acetaminophen, or other generic analgesics not tried first
- 2. Non-formulary status (new-to-market block)
- 3. Days-supply or quantity limit exceeded
- 4. Acute pain etiology and severity not documented
- 5. Contraindication to opioids or NSAIDs not documented
What to Include in a Journavx Letter of Medical Necessity
Document the acute pain condition and severity, prior or contraindicated analgesics (NSAID GI/renal/cardiovascular risk, acetaminophen inadequacy), opioid risk factors (history of substance use disorder, respiratory risk, concurrent sedatives, patient preference to avoid opioids), and the expected short treatment duration. Cite the CDC 2022 guideline recommendation to maximize non-opioid therapies.
Key clinical evidence to cite:
- ✓ Two randomized, placebo-controlled Phase 3 trials (post-abdominoplasty and post-bunionectomy) showing significant pain reduction vs placebo
- ✓ Single-arm Phase 3 safety and effectiveness study across a range of surgical and non-surgical acute pain conditions
- ✓ First-in-class non-opioid mechanism, FDA-approved January 2025, with no evidence of addictive potential in clinical studies
Relevant guidelines:
- 📖 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Pain
- 📖 ASA/APS Acute Postoperative Pain Management Guidance
- 📖 HHS Pain Management Best Practices Inter-Agency Task Force Report
Journavx Prior Authorization Criteria
Standard criteria across major US payers for Journavx. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy: generic NSAIDs, acetaminophen, or other generic analgesics not tried first
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Journavx
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Journavx Prior Authorization FAQ
Why was my Journavx prior authorization denied?
The most common denial reasons for Journavx are: Step therapy: generic NSAIDs, acetaminophen, or other generic analgesics not tried first; Non-formulary status (new-to-market block); Days-supply or quantity limit exceeded; Acute pain etiology and severity not documented; Contraindication to opioids or NSAIDs not documented.
What should a Journavx Letter of Medical Necessity include?
Document the acute pain condition and severity, prior or contraindicated analgesics (NSAID GI/renal/cardiovascular risk, acetaminophen inadequacy), opioid risk factors (history of substance use disorder, respiratory risk, concurrent sedatives, patient preference to avoid opioids), and the expected short treatment duration. Cite the CDC 2022 guideline recommendation to maximize non-opioid therapies.
Which payers cover Journavx?
Journavx is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.